Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6243674 | 0.85 | KCNH2 (0.50) | PTGS2LOXL2KCNH2JAK2NR1H2 | |
| SCHEMBL2140712 | 0.79 | PTGS2 (0.53) | PTGS2LOXL2KCNH2NR1H2NR1H3 | |
| SCHEMBL10051059 | 0.78 | CA1 (0.55) | LOXL2 | |
| SCHEMBL17153735 | 0.76 | PTGS2 (0.50) | PTGS2LOXL2KCNH2NR1H2NR1H3 | |
| SCHEMBL14320520 | 0.74 | CA12 (0.58) | PTGS2LOXL2KCNH2JAK2 | |
| SCHEMBL3007986 | 0.74 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL8770103 | 0.73 | KCNH2 (0.49) | PTGS2LOXL2KCNH2NR1H2NR1H3 | |
| SCHEMBL145847 | 0.73 | NR1H2 (0.45) | LOXL2KCNH2JAK2NR1H2CTSS | |
| SCHEMBL30690007 | 0.73 | ALOX5 (0.53) | LOXL2KCNH2NR1H2NR1H3 | |
| SCHEMBL5831675 | 0.73 | PTGS2 (0.56) | PTGS2NPY5RPTGS1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076324-B2 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20100204206-A1 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204206-A1 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A2, RYR2 | PTGS2 455/4885LOXL2 3763/4885KCNH2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.